产前Tdap免疫与孕产妇及新生儿不良事件风险
基于2010-2014年大型保险理赔数据库的队列研究,识别1,079,034次分娩及677,075名关联新生儿,评估产前Tdap免疫与不良出生结局的关联。 optimally-timed免疫与绒毛膜羊膜炎(RR=1.11,95%CI 1.07-1.15,总体风险2.8%)及产后出血(RR=1.23,95%CI 1.18-1.28,总体风险2.4%)的相对风险小幅升高相关,但绝对风险增加低;Tdap与任何新生儿不良结局风险升高无关。
要点
- 产前Tdap免疫与新生儿不良结局风险升高无关。
- optimally-timed免疫与绒毛膜羊膜炎及产后出血相对风险小幅升高相关,绝对风险增加低。
- 绒毛膜羊膜炎关联与既往一项研究一致,产后出血关联需进一步研究。
核心结论
- 总体而言,产前Tdap免疫与新生儿不良事件无关,但与绒毛膜羊膜炎的潜在关联与既往一项研究一致,且与产后出血的关联需进一步研究。
研究设计与样本
- 在大型保险理赔数据库(2010-2014年)中识别分娩孕妇,Tdap免疫分为 optimal prenatal(27+周)、early prenatal(<27周)、postpartum(产后≤7天)或无。
- 采用倾向评分加权对数二项回归和Cox比例风险模型估计风险比(RR)和风险比(HR)。
- 识别1,079,034次分娩和677,075名关联新生儿;11.5%为 optimal 免疫,2.3%为 early 免疫。
主要发现
- 免疫后过敏反应1例,孕产妇脑病12例(均为产后),无吉兰-巴雷综合征(GBS)病例。
- optimally-timed免疫与绒毛膜羊膜炎相对风险小幅升高相关(RR=1.11,95%CI 1.07-1.15,总体风险2.8%)。
- optimally-timed免疫与产后出血相对风险小幅升高相关(RR=1.23,95%CI 1.18-1.28,总体风险2.4%)。
- 上述相对风险升高对应较低的绝对风险增加。
- Tdap与任何新生儿不良结局风险升高无关。
局限性
- 潜在关联与绒毛膜羊膜炎一致于既往一项研究,且产后出血关联需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many countries recommend combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis immunization (Tdap) during pregnancy to stimulate transplacental transmission of pertussis antibodies to newborns. The immune system can be altered during pregnancy, potentially resulting in differing immunization risks in pregnant women. The safety of widespread Tdap immunization during pregnancy needs to be established. Our objective was to assess whether prenatal Tdap immunization was associated with adverse birth outcomes, and to evaluate the effect of timing of Tdap administration on these outcomes. We identified pregnancies at delivery in a large insurance claims database (2010-2014). Tdap immunization was categorized as optimal prenatal (27+weeks), early prenatal (<27weeks), postpartum (≤7days post-delivery), or none. Medical claims were searched to identify maternal adverse immunization reactions (e.g. anaphylaxis, fever, Guillian-Barre syndrome [GBS]), adverse birth outcomes (e.g. preeclampsia/eclampsia, premature rupture or membranes, chorioamnionitis) and newborn outcomes (e.g. respiratory distress, pulmonary hypertension, neonatal jaundice). Women with optimal or early prenatal Tdap were compared to those not immunized in pregnancy, using propensity score-weighted log-binomial regression and Cox proportional hazards models to estimate risk ratios (RR) and hazard ratios (HR). We identified 1,079,034 deliveries and 677,075 linked newborns; 11.5% were immunized optimally and 2.3% immunized early. There were 1 case of post-immunization anaphylaxis, and 12 cases of maternal encephalopathy (all post- delivery); there were no cases of GBS. Optimally-timed immunization was associated with small increased relative risks of: chorioamnionitis [RR=1.11, (95% CI: 1.07-1.15), overall risk=2.8%], and postpartum hemorrhage [RR=1.23 (95% DI: 1.18-1.28), overall risk=2.4%]; however, these relative increases corresponded to low absolute risk increases. Tdap was not associated with increased risk of any adverse newborn outcome. Overall, prenatal Tdap immunization was not associated with newborn adverse events, but potential associations with chorioamnionitis consistent with one previous study and postpartum hemorrhage require further investigation.
引用
- Layton JB, Butler AM, Li D, et al. Prenatal Tdap immunization and risk of maternal and newborn adverse events. Vaccine. 2017. PMID: 28669620. doi:10.1016/j.vaccine.2017.06.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。